Not exact matches
It's only been tested
on mice so far, but the results are tremendously promising for an antibody Stanford researchers have been
experimenting with that blocks the body from «eating»
cancer cells.
In
experiments on normal and MLL
cells from mice and humans, the researchers demonstrated that beta - catenin is activated in
cancer stem
cells that prompt leukaemic blood
cells to multiply.
«In our
experiments, our nanoparticles successfully delivered a test gene to brain
cancer cells in mice, where it was then turned
on,» says Jordan Green, Ph.D., an assistant professor of biomedical engineering and neurosurgery at the Johns Hopkins University School of Medicine.
To test their hypothesis, the researchers carried out
experiments on human melanoma
cells, a line of
cancer cells they chose for their ability to grow easily and quickly.
In
experiments on dog
cancer cells in the laboratory it was found that the newly developed antibodies did, in fact, bind to canine
cancer cells with greater specificity.
The researchers performed lab
experiments on cells derived from a cervical
cancer and found that when DOHH is blocked, a protein known as eIF5A fails to mature.
«Our
experiments showed that restoring H19 expression hindered by too much p53 restored «protective differentiation» of osteoblasts to counter events of tumor growth early
on in bone
cancer,» said co-author, Ihor Lemischka, PhD, Director of The Black Family Stem
Cell Institute within the Icahn School of Medicine.
Experiments on pancreas organoids — models that are essentially balls of
cells sampled from the pancreas of healthy people and pancreatic
cancer patients — showed that lowering antioxidant levels within cancerous pancreas
cells, or
cells on the way to becoming cancerous, kills them.
In co-culture
experiments on coated transfilters, both NAFs and CAFs induced migration and invasion of HT29, which are intrinsically noninvasive colon
cancer cells.
Researchers can also find information
on the
cancer cell lines that are most suitable for their
experiments.
Fortunately,
experiments done by Dr. Jan Vijg at the Albert Einstein College of Medicine and others
on mutations (changes in base sequence in DNA) and additional studies commissioned by SENS Research Foundation
on epimutations (changes in the arrangement of methyl groups) suggest that these latter kinds of alterations - the kind that accumulate in
cells without triggering apoptosis or senescence or contributing to
cancer - accumulate too slowly to make a difference with the current lifespan.
In the
experiments described in the paper, the MGH team confirmed that their mesothelin - targeting fusion protein binds to mesothelin
on either ovarian
cancer or mesothelioma
cells, activates dendritic
cells, and enhances the
cells» processing and presentation of several different tumor antigens, inducing a number of T -
cell - based immune responses.
In the study, which was published last year in Nature, researchers
experimented with various types of dietary restriction, using fluorescent proteins to mark
cancer cells and determine the effect of fasting
on levels.
Since these
experiments were only performed
on cancer cells in test tubes, the researchers took the next step and ran tests
on breast
cancer tumors in live mice.
Part of the talk discussed results of
experiments which showed the inhibiting effects of diet (plant substances)
on cancer cell growth.